BCL6 as a therapeutic target for lymphoma
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: B cell lymphoma 6 (BCL6) is a transcriptional repressor critical for the development and maintenance of germinal centers (GCs), which are required for generation of an effective humoral immune response. Genomic aberrations of BCL6, including mutations and translocations that occur during the GC reaction, as well as alterations of genes that regulate BCL6 expression, lead to sustained activity of BCL6, which promotes the development of GC-derived lymphomas. Since many types of B cell non-Hodgkin lymphomas (B-NHL) arise from neoplastic transformation of GC B cells and a high proportion harbor genetic lesions that deregulate BCL6 expression, inhibition of BCL6 has emerged as an attractive therapeutic strategy for lymphomas. Areas covered: This review examines the rationale for and challenges in therapeutic targeting of BCL6 in lymphomas. We describe approaches that have been used and are currently being considered for inhibition of BCL6. Expert opinion: Several BCL6 inhibiting agents, including peptidomimetics, small molecules, and natural compounds, most of which target the BTB domain of the protein at the corepressor binding site, have been developed with demonstration of anti-lymphoma activity in preclinical models. Future clinical trials will be important to investigate the efficacy of targeting BCL6 in B-NHL (and other neoplasms), particularly in combination with other therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bcl6 mediates the development of T follicular helper cells
Nurieva, R. I., Chung, Y., Martinez, G. J., Yang, X. O., Tanaka, S., Matskevitch, T. D., Wang, Y.-H., & Dong, C. (2009) · Science · doi:10.1126/science.1176676 · Cited by 1,506 · cited 1×
“More importantly and of pertinence to the GC and humoral immune responses, a series of studies by different investigators led to the recognition of BCL6 as a master regulator of CD4+ follicular helper T cell (TFH) differentiation [45,46].”
BackgroundGerminal centres and B cell lymphomagenesis
Basso, K., & Dalla-Favera, R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3814 · Cited by 510
Cattoretti, G., Pasqualucci, L., Ballon, G., Tam, W., Nandula, S. V., Shen, Q., Mo, T., Murty, V. V., & Dalla-Favera, R. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.037 · Cited by 383 · cited 1×
“However, deregulated and continual expression of BCL6 allows for the persistence of B-cells in a DNA-damage-tolerant state and can lead to the development of B-NHL in mice, likely via the acquisition of additional somatic mutations in oncogenes and tumor suppressor genes [66].”
BackgroundDirect Repression of prdm1 by Bcl-6 Inhibits Plasmacytic Differentiation
Tunyaplin, C., Shaffer, A. L., Angelin-Duclos, C. D., Yu, X., Staudt, L. M., & Calame, K. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1158 · Cited by 376
Phan, R. T., Saito, M., Basso, K., Niu, H., & Dalla-Favera, R. (2005) · Nature Immunology · doi:10.1038/ni1245 · Cited by 343
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.050 · Cited by 288 · cited 1×
“The GI50, however, was high (approximately 200 μM) [56].”
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas
Jiang, Y., Ortega-Molina, A., Geng, H., Ying, H.-Y., Hatzi, K., Parsa, S., McNally, D., Wang, L., Doane, A. S., Agirre, X., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0975 · Cited by 278
BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms
Hatzi, K., Nance, J. P., Kroenke, M. A., Bothwell, M., Haddad, E. K., Melnick, A., & Crotty, S. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141380 · Cited by 261 · cited 6×
“One study demonstrated that, in TFH, BCL6 appears to antagonize the IL-7R-STAT5 signaling pathway and decreases cellular levels of 5-hydroxymethylcytosine [49], while in a different ChIPseq analysis, BCL6 was found to associate with AP-1 binding motifs in TFH, leading to the proposal that part of the role of BCL6 in T…”
BackgroundInfluentialBéguelin, W., Teater, M., Gearhart, M. D., Calvo Fernández, M. T., Goldstein, R. L., Cárdenas, M. G., Hatzi, K., Rosen, M., Shen, H., Corcoran, C. M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.006 · Cited by 254 · cited 1×
“these two mediators in lymphoma models [96].”
Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6
Kerres, N., Steurer, S., Schlager, S., Bader, G., Berger, H., Caligiuri, M., Dank, C., Engen, J. R., Ettmayer, P., Fischerauer, B., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.081 · Cited by 207
Cited by
Ran, X., & Gestwicki, J. E. (2018) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2018.06.004 · Cited by 263
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
Development of covalent inhibitors: Principle, design, and application in cancer
Zheng, L., Li, Y., Wu, D., Xiao, H., Zheng, S., Wang, G., & Sun, Q. (2023) · MedComm – Oncology · doi:10.1002/mog2.56 · Cited by 71
Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis
Schlager, S., Salomon, C., Olt, S., Albrecht, C., Ebert, A., Bergner, O., Wachter, J., Trapani, F., Gerlach, D., Voss, T., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27506 · Cited by 36
“A variety of BCL6 inhibitors have been previously reported, several of which have demonstrated that the BTB domain of BCL6 is amenable to targeting with peptide and small molecule inhibitors (reviewed in [18]) as well as PROTACs [19].”
Background
Metadata
- Authors
- Leeman-Neill, R. J., & Bhagat, G.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2018-01-04
- Volume
- 22
- Issue
- 2
- Pages
- 143-152
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2776622814
- Cited by
- 84
- References
- 15
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BCL6 as a therapeutic target for lymphoma. https://app.cochat.ai/papers/10.1080/14728222.2018.1420782
- The paper
- Leeman-Neill, R. J., & Bhagat, G. (2018). BCL6 as a therapeutic target for lymphoma. Expert Opinion on Therapeutic Targets. https://doi.org/10.1080/14728222.2018.1420782
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.